2022 News Archive

December 19th, 2022: RADICAVA® Oral Suspension Receives Positive Recommendation from INESSS

November 24th, 2022: CADTH has issued positive draft recommendation for RADICAVA® Oral Suspension!

November 22nd, 2022: Help the ALS Society of BC Show the Power of Hope

November 16th, 2022: John Goyer Memorial ALS Charity Golf Tournament

November 15th, 2022: Why Volunteer at the ALS Society of BC?

November 9th, 2022: Mitsubishi Tanabe Pharma Canada announces Canadian authorization of Radicava® (Edaravone) Oral Suspension.

November 8th, 2022: What is the ALS Society of BC’s Equipment Loan Program?

November 3rd, 2022: Leaders needed for Williams Lake and Mid-Island Move to Cure ALS Locations

November 1st, 2022: Why is the ALS Society of BC Participating in the 2022 GivingTuesday Movement?

October 25th, 2022: Save the Date for GivingTuesday 2022!

October 6th, 2022: Coast Hotels Supports British Columbia Charities with Funds Raised from 20th Annual Golf Tournament. Click here to read the press release.

October 4th, 2022: Watch our 2022 Thanksgiving video on why our society is feeling blessed and thankful this year. 🙏💙

September 9th, 2022: Congratulations to Kim Moffat from Salmon Arm, BC, on winning the “2022 Fly Away Raffle WestJet Voucher Trip For 2” on September 9th. Click here to learn more.

June 30th, 2022: Congratulations to Peter Grant from Victoria, BC, on winning the “2022 Move to Cure ALS 50/50 Raffle” on June 30th. Click here to learn more.

June 18th, 2022: Congratulations to Zeni Maartman from Nanaimo on winning the “Win a Trip for 2 Anywhere WestJet Flies!” raffle at the Move to Cure ALS Mid-Island event on June 18th, 2022. Click here to learn more.

June 13th, 2022: Amylyx Pharmaceuticals announces that Health Canada has given approval of ALBRIOZA™ for the treatment of ALS, this is the first new therapy to be approved in our country since 2018. Read about it by clicking here.

May 18th, 2022: The ALS Society of BC is pleased to announce Marlee Wilson from Burns Lake as the recipient of the 2022 Cycle of Hope Lemon“aid” Education Fund. Click here to learn more.

May 6th, 2022: The province of British Columbia has proclaimed June 2022 as Amyotrophic Lateral Sclerosis (ALS) Awareness Month in British Columbia Click here to view the proclamation.

April 19th, 2022: ALS NEWS TODAY: The Canadian province of British Columbia is giving another CA$2 million (about $1.65 million) to help establish “Project Hope” — what organizers hope will be a world-class amyotrophic lateral sclerosis (ALS) center at the University of British Columbia (UBC). Click here to view the full article.

April 6th, 2022: The Province is investing $2 million through the ALS Society of BC for the second phase of PROJECT HOPE to further support British Columbians living with amyotrophic lateral sclerosis (ALS). Click here to view the full announcement.

March 31st, 2022: Amylyx announced today the outcome of the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous System Drugs Advisory Committee (PCNSDAC) meeting to review the Company’s New Drug Application (NDA) for AMX0035 for the treatment of amyotrophic lateral sclerosis was not approved. Click here to learn more.

February 23rd, 2022: AB Science announces that Health Canada has granted authorization to file a New Drug Submission for masitinib in the treatment of ALS under the Notice of Compliance with Conditions (NOC/c) policy. Click here to learn more.

February 17th, 2022: Thank you to the BC Liberal Caucus for their ongoing support of Project Hope as we aim to bring cutting edge research to BC to find a cure. The BC Liberals have sent a formal letter to Premier Horgan urge his government to continue providing support to the ALS Society of BC’s transition into the second phase of Project Hope, which will enable clinical trials and further research into Amyotrophic Lateral Sclerosis (ALS) here in British Columbia. Click here to view the letter from the BC Liberal Caucus.

February 3rd, 2022: The Canadian Neuromuscular Disease Registry (CNDR), an independent, academic registry based out of the University of Calgary, and Amylyx Pharmaceuticals (NASDAQ: AMLX) today announced they are partnering on a real‐world evidence generation initiative for Amylyx’ novel investigational therapy AMX0035 (sodium phenylbutyrate (PB) and ursodoxicoltaurine (TURSO; also known as taurursodiol)), for the treatment of amyotrophic lateral sclerosis (ALS). Click here for the latest press release.

January 19th, 2022: The ALS Society of British Columbia is excited to introduce the new Move to Cure ALS! Registration is now open! The Move to Cure ALS is the annual signature fundraising event for the ALS Society of British Columbia. All funds raised will stay in BC & the Yukon to support patient services and PROJECT HOPE. Let’s move together this June to raise awareness & funds for people living with ALS in BC. Visit: www.movetocureals.ca to learn more.